These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24896325)

  • 1. Targeting myeloid differentiation 2 for treatment of sepsis.
    Duan G; Zhu J; Xu J; Liu Y
    Front Biosci (Landmark Ed); 2014 Jun; 19(6):904-15. PubMed ID: 24896325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid differentiation 2 as a therapeutic target of inflammatory disorders.
    Park SH; Kim ND; Jung JK; Lee CK; Han SB; Kim Y
    Pharmacol Ther; 2012 Mar; 133(3):291-8. PubMed ID: 22119168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran.
    Kim HM; Park BS; Kim JI; Kim SE; Lee J; Oh SC; Enkhbayar P; Matsushima N; Lee H; Yoo OJ; Lee JO
    Cell; 2007 Sep; 130(5):906-17. PubMed ID: 17803912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
    Mishra V; Pathak C
    J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
    Opal SM; Laterre PF; Francois B; LaRosa SP; Angus DC; Mira JP; Wittebole X; Dugernier T; Perrotin D; Tidswell M; Jauregui L; Krell K; Pachl J; Takahashi T; Peckelsen C; Cordasco E; Chang CS; Oeyen S; Aikawa N; Maruyama T; Schein R; Kalil AC; Van Nuffelen M; Lynn M; Rossignol DP; Gogate J; Roberts MB; Wheeler JL; Vincent JL;
    JAMA; 2013 Mar; 309(11):1154-62. PubMed ID: 23512062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo Toll-like receptor 4 antagonism restores cardiac function during endotoxemia.
    Ehrentraut S; Lohner R; Schwederski M; Ehrentraut H; Boehm O; Noga S; Langhoff P; Baumgarten G; Meyer R; Knuefermann P
    Shock; 2011 Dec; 36(6):613-20. PubMed ID: 22089127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-endotoxic activity and structural basis for human MD-2·TLR4 antagonism of tetraacylated lipid A mimetics based on βGlcN(1↔1)αGlcN scaffold.
    Garate JA; Stöckl J; Fernández-Alonso Mdel C; Artner D; Haegman M; Oostenbrink C; Jiménez-Barbero J; Beyaert R; Heine H; Kosma P; Zamyatina A
    Innate Immun; 2015 Jul; 21(5):490-503. PubMed ID: 25394365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.
    Barochia A; Solomon S; Cui X; Natanson C; Eichacker PQ
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):479-94. PubMed ID: 21323610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma.
    Korff S; Loughran P; Cai C; Lee YS; Scott M; Billiar TR
    J Surg Res; 2013 Oct; 184(2):e17-25. PubMed ID: 23777984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin Analog L48H37 Prevents Lipopolysaccharide-Induced TLR4 Signaling Pathway Activation and Sepsis via Targeting MD2.
    Wang Y; Shan X; Dai Y; Jiang L; Chen G; Zhang Y; Wang Z; Dong L; Wu J; Guo G; Liang G
    J Pharmacol Exp Ther; 2015 Jun; 353(3):539-50. PubMed ID: 25862641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eritoran inhibits S100A8-mediated TLR4/MD-2 activation and tumor growth by changing the immune microenvironment.
    Deguchi A; Tomita T; Ohto U; Takemura K; Kitao A; Akashi-Takamura S; Miyake K; Maru Y
    Oncogene; 2016 Mar; 35(11):1445-56. PubMed ID: 26165843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor 4 modulation as a strategy to treat sepsis.
    Wittebole X; Castanares-Zapatero D; Laterre PF
    Mediators Inflamm; 2010; 2010():568396. PubMed ID: 20396414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564).
    Sun Y; Pearlman E
    Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1247-54. PubMed ID: 18936141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2.
    Ohto U; Fukase K; Miyake K; Shimizu T
    Proc Natl Acad Sci U S A; 2012 May; 109(19):7421-6. PubMed ID: 22532668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zhankuic acid A isolated from Taiwanofungus camphoratus is a novel selective TLR4/MD-2 antagonist with anti-inflammatory properties.
    Chen YF; Shiau AL; Wang SH; Yang JS; Chang SJ; Wu CL; Wu TS
    J Immunol; 2014 Mar; 192(6):2778-86. PubMed ID: 24532584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial watch: Sepsis study failure highlights need for trial design rethink.
    Tse MT
    Nat Rev Drug Discov; 2013 May; 12(5):334. PubMed ID: 23629495
    [No Abstract]   [Full Text] [Related]  

  • 17. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis.
    Tidswell M; LaRosa SP
    Expert Rev Anti Infect Ther; 2011 May; 9(5):507-20. PubMed ID: 21609262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid differentiation protein 2 silencing decreases LPS-induced cytokine production and TLR4/MyD88 pathway activity in alveolar macrophages.
    Ren W; Hu L; Hua F; Jin J; Wang Y; Zhu L
    Immunol Lett; 2011 Dec; 141(1):94-101. PubMed ID: 21849156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2.
    Visintin A; Halmen KA; Latz E; Monks BG; Golenbock DT
    J Immunol; 2005 Nov; 175(10):6465-72. PubMed ID: 16272300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailored Modulation of Cellular Pro-inflammatory Responses With Disaccharide Lipid A Mimetics.
    Heine H; Adanitsch F; Peternelj TT; Haegman M; Kasper C; Ittig S; Beyaert R; Jerala R; Zamyatina A
    Front Immunol; 2021; 12():631797. PubMed ID: 33815382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.